2023
Inhibition of T-cell activity in alopecia areata: recent developments and new directions
Passeron T, King B, Seneschal J, Steinhoff M, Jabbari A, Ohyama M, Tobin D, Randhawa S, Winkler A, Telliez J, Martin D, Lejeune A. Inhibition of T-cell activity in alopecia areata: recent developments and new directions. Frontiers In Immunology 2023, 14: 1243556. PMID: 38022501, PMCID: PMC10657858, DOI: 10.3389/fimmu.2023.1243556.Peer-Reviewed Original ResearchConceptsT cell-signaling pathwaysAlopecia areataT cellsEtiopathogenesis of AAPathogenesis of AATreatment of AAImmune privilege collapseOnly US FoodHair folliclesSevere alopecia areataT cell activityT cell receptor recognitionLoss of scalpSystemic medicationsAA therapyCytotoxic CD8Inflammatory pathogenesisAutoimmune diseasesTreatment optionsHair lossLimited efficacyTherapeutic pathwaysClinical developmentJAK inhibitionUS Food
2016
Tofacitinib for the treatment of alopecia areata and variants in adolescents
Craiglow BG, Liu LY, King BA. Tofacitinib for the treatment of alopecia areata and variants in adolescents. Journal Of The American Academy Of Dermatology 2016, 76: 29-32. PMID: 27816292, DOI: 10.1016/j.jaad.2016.09.006.Peer-Reviewed Original ResearchConceptsAlopecia areataAdverse eventsAdolescent patientsTreatment of AASignificant hair regrowthUse of tofacitinibMonths of treatmentProspective clinical trialsMedian percent changeJanus kinase inhibitorSeverity of diseaseReview of systemsSALT scoreAlopecia ToolLaboratory monitoringPhysical examinationHair regrowthClinical trialsEffective therapyPromising therapyRetrospective natureTofacitinibControl groupPatientsPercent changeSafety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
Crispin M, Ko JM, Craiglow BG, Li S, Shankar G, Urban JR, Chen JC, Cerise JE, Jabbari A, Winge M, Marinkovich MP, Christiano AM, Oro AE, King BA. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight 2016, 1: e89776. PMID: 27699252, PMCID: PMC5033755, DOI: 10.1172/jci.insight.89776.Peer-Reviewed Original ResearchConceptsAlopecia areataAlopecia totalisAlopecia universalisHair lossDisease activity index scoreTreatment of AANational Alopecia Areata FoundationActivity index scoreCompletion of therapySevere alopecia areataSingle-arm trialNational Psoriasis FoundationScalp hair lossNational InstituteVeterans Affairs OfficePan-JAK inhibitorAdverse eventsDrug cessationDurable responsesAlopecia ToolDisease relapseTherapeutic optionsAutoimmune diseasesEffective therapyGrade I